Showing results (411-420 of 550) with videos related to

Sort By:
Pageof 55
Alimentary Pharmacology & Therapeutics|September 2, 2021
Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expressionMadhusudan Grover, Antonio Berumen, Stephanie Peters, et al.
Gastrointestinal Endoscopy|March 22, 2017
Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitisMarietta Iacucci, Marco Daperno, Mark Lazarev, et al.
Gastrointestinal Endoscopy|June 21, 2015
Deep enteroscopy with a conventional colonoscope: initial multicenter study by using a through-the-scope balloon catheter systemRabia Ali, Daniel Wild, Frederick Shieh, et al.
Gastroenterology|August 31, 2011
Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophagesRaja Atreya, Michael Zimmer, Brigitte Bartsch, et al.
Zeitschrift Fur Gastroenterologie|June 7, 2022
[Position paper on reporting of intestinal ultrasound findings in patients with inflammatory bowel disease]Torsten Kucharzik, Raja Atreya, Oliver Bachmann, et al.
Cell Reports|September 16, 2020
Toll-like Receptor 5 Activation by the CagY Repeat Domains of Helicobacter pyloriNicole Tegtmeyer, Matthias Neddermann, Judith Lind, et al.
Journal of Crohn'S & Colitis|July 6, 2022
PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial CellsKatharina Gerlach, Vanessa Popp, Stefan Wirtz, et al.
Histopathology|April 19, 2018
The outlet patch: gastric heterotopia of the colorectum and anusAbul A S R Mannan, Michael Vieth, Armen Khararjian, et al.
Nature Immunology|June 9, 2014
TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cellsKatharina Gerlach, YouYi Hwang, Alexej Nikolaev, et al.
Helicobacter|November 9, 2011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infectionStephan Miehlke, Susanne Krasz, Wulf Schneider-Brachert, et al.
Pageof 55